货号:A320047
同义名:
Phentolamine methanesulfonate; Phentolamine mesylate
Phentolamine methanesulfonate salt 是一种 α-肾上腺素受体拮抗剂,常被用于高血压及勃起功能障碍机制研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Adrenergic Receptor ↓ ↑ | α-adrenergic receptor ↓ ↑ | β-adrenergic receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ivabradine HCl | ✔ | 98% | |||||||||||||||||
| Maprotiline HCl | ✔ | 98% | |||||||||||||||||
| Cisatracurium besylate | ✔ | 96% | |||||||||||||||||
| Yohimbine HCI | ✔ | 99+% | |||||||||||||||||
| BMY 7378 |
++
α1D-adrenoceptor, pKi: 5.1 α2C-adrenoceptor, pKi: 6.54 |
+
β1-adrenoceptor, pIC50: 5.1 |
97% | ||||||||||||||||
| Asenapine maleate |
++++
α2A-adrenergic receptor, pKi: 8.9 α2B-adrenergic receptor, pKi: 8.9 |
97% | |||||||||||||||||
| Piribedil |
++
adrenoceptor α2C, pKi: 7.2 adrenoceptor α2A, pKi: 7.1 |
98% | |||||||||||||||||
| Prazosin HCl | ✔ | 95% | |||||||||||||||||
| Silodosin | ✔ | 98% | |||||||||||||||||
| Phenoxybenzamine HCl | ✔ | 98% | |||||||||||||||||
| Labetalol HCl | ✔ | 98+% | |||||||||||||||||
| Naftopidil |
+++
α1D-adrenergic receptor, Ki: 20 nM α1A-adrenergic receptor, Ki: 3.7 nM |
98% | |||||||||||||||||
| Naftopidil 2HCl |
+
α1-adrenergic receptor, IC50: 0.2 μM |
99% | |||||||||||||||||
| Alfuzosin HCl | ✔ | 98% | |||||||||||||||||
| Terazosin HCl | ✔ | 99% | |||||||||||||||||
| Atipamezole | ✔ | 95% | |||||||||||||||||
| Phentolamine methanesulfonate salt | ✔ | 99% | |||||||||||||||||
| Carvedilol | ✔ | 99% | |||||||||||||||||
| Doxazosin mesylate | ✔ | 99% | |||||||||||||||||
| Tolazoline HCl | ✔ | 98% | |||||||||||||||||
| Esmolol HCl | ✔ | 95% | |||||||||||||||||
| Propranolol HCl |
++
β-adrenergic receptor, IC50: 12 nM |
99% | |||||||||||||||||
| Zenidolol HCl |
++++
β2-adrenergic receptor, Ki: 0.7nM β1-adrenergic receptor, Ki: 611nM |
98% | |||||||||||||||||
| Acebutolol HCl | ✔ | 97+% | |||||||||||||||||
| Carteolol HCl | ✔ | 98+% | |||||||||||||||||
| Betaxolol | ✔ | 99% | |||||||||||||||||
| Betaxolol HCl |
+
β1-adrenergic receptor, IC50: 6 μM |
97% | |||||||||||||||||
| Bisoprolol | ✔ | 97% | |||||||||||||||||
| Sotalol HCl | ✔ | 95+% | |||||||||||||||||
| Nebivolol HCl |
+++
β1-adrenoceptor, IC50: 0.8 nM |
99% | |||||||||||||||||
| Metoprolol | ✔ | 98+% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Phentolamine mesylate (OraVerse), a nonselective a-adrenergic blocking drug, is the first therapeutic agent marketed for the reversal of soft-tissue anaesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anaesthetic containing a vasoconstrictor[3]. Phentolamine mesylate (PM) is widely used to reverse local anesthesia after dental procedures. PM substantially reduced the time to recovery of normal sensation and function after local anesthesia in routine dental treatment[4]. Phentolamine leads to an increase in FBM (fetal breathing movements) by preferentially antagonizing presynaptic alpha 2-adrenoreceptors over postsynaptic alpha 1-adrenoreceptors. This influence of phentolamine on FBM may be secondary to its effect on ECoG (electrocortical activity). Promotion of LV-ECoG by catecholamines is mediated via an alpha 1-independent mechanism[5]. Phentolamine mesylate, at dosages from 0.4 to 0.8 mg in adults and adolescents and at dosages from 0.2 to 0.4 mg in children aged 4 to 11 years, has been proven to be safe. Its ability to block a-adrenergic receptors on blood vessels induces vasodilation and enhances the redistribution of the local anesthetic away from the injection site[6]. |
| Concentration | Treated Time | Description | References | |
| Rabbit aortic spiral strips | 0.1 µM | 2 hours | To investigate the inhibitory effect of phentolamine on ergonovine-induced contractions in normal and atherosclerotic rabbit aortic spiral strips. Results showed that 0.1 μM phentolamine inhibited 1 μM ergonovine-induced contractions by 71% in normal arteries, while the same concentration of phentolamine only inhibited 54% in atherosclerotic arteries. | Mediation by a serotonergic mechanism. J Clin Invest. |
| Human periodontal ligament fibroblasts (HPDLFs) | 25 µM | 24 hours or 48 hours | To investigate the effect of phentolamine on LPS-inhibited HPDLF proliferation, results showed that phentolamine significantly ameliorated LPS-inhibited cell proliferation. | Exp Mol Med. 2014 Oct 17;46(10):e118. |
| Rabbit right atrium | 0.1-10 µM | 30 minutes | Phentolamine inhibited the tachycardia induced by field stimulation in a concentration-dependent manner. This effect was prevented by benextramine treatment and antagonized 10-fold by yohimbine (1 μM) but not by prazosin (0.1 μM). | Br J Pharmacol. 1984 Mar;81(3):423-5. |
| Mouse pancreatic β-cells | 20-100 µM | To study the inhibitory effects of phentolamine on ATP-sensitive K+ channels, results showed phentolamine significantly inhibited 86Rb efflux and ATP-sensitive K+ currents. | Br J Pharmacol. 1990 Sep;101(1):115-20. | |
| Mouse pancreatic β-cells | 10 µM | To investigate the inhibitory effect of Phentolamine on ATP-sensitive K+ channels and its impact on insulin release. Results showed that Phentolamine inhibited 86Rb efflux, indicating blockade of ATP-sensitive K+ channels, thereby increasing insulin release. | Br J Pharmacol. 1992 Sep;107(1):8-14. | |
| Guinea-pig detrusor smooth muscle cells | 3 µM - 100 µM | To investigate the effect of phentolamine on rhythmic contractions of detrusor muscle, results showed phentolamine induced concentration-dependent rhythmic contractions without affecting basal tone | Br J Pharmacol. 1984 Dec;83(4):965-71. |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Wistar WI/Ico, Wistar WAG/Rij, Fischer 344 | Perfusion and superfusion | 1 µM | 10 minutes | To evaluate the efficiency of α2-adrenoceptor-mediated inhibition of noradrenaline release, results showed an increase in noradrenaline release in all ages and strains. | Br J Pharmacol. 1994 Oct;113(2):363-8 |
| Mice | Pancreatic β-cells | Perifusion | 20-100 μM | To study the inhibitory effects of phentolamine on ATP-sensitive K+ channels, results showed phentolamine significantly inhibited 86Rb efflux and ATP-sensitive K+ currents. | Br J Pharmacol. 1990 Sep;101(1):115-20. | |
| Guinea-pig | Detrusor smooth muscle strips | Tissue bath | 3 μM -100 μM | Single administration | To investigate the effect of phentolamine on rhythmic contractions of detrusor muscle, results showed phentolamine induced concentration-dependent rhythmic contractions without affecting basal tone | Br J Pharmacol. 1984 Dec;83(4):965-71. |
| Rabbit | Ganglion-blocked conscious or anaesthetized rabbits | Intravenous injection | 3-1000 μg/kg | Single injection | Phentolamine caused a dose-related rise in blood pressure in ganglion-blocked rabbits, which was antagonized by yohimbine (1 mg kg-1). In rabbits without ganglion blockade, phentolamine did not evoke a pressor response. | Br J Pharmacol. 1984 Mar;81(3):423-5. |
| Sprague-Dawley rats | Hippocampal slices | Perfusion | 50 μM | 30 minutes | To study the long-term effects of NE and phentolamine on synaptic responses in the hippocampal dentate gyrus. Results showed that NE and phentolamine selectively potentiated responses to medial PP stimulation while depressing responses to lateral PP stimulation. | Proc Natl Acad Sci U S A. 1989 Jun;86(12):4776-80 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03240822 | Urologic Injuries ... 展开 >> Genital Diseases, Male Amputation 收起 << | Phase 1 | Recruiting | December 2025 | United States, North Carolina ... 展开 >> Wake Forest School of Medicine Recruiting Winston-Salem, North Carolina, United States, 27104 Contact: Mary-Clare Day, RN BSN 336-713-1343 Mday@wakehealth.edu 收起 << |
| NCT01422616 | Ischemic Stroke ... 展开 >> High Blood Pressure 收起 << | Phase 3 | Recruiting | February 2019 | Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Recruiting Sydney, New South Wales, Australia, 2050 Contact: Craig S Anderson, MD +61 2 933 4500 canderson@georgeinstitute.org.au 收起 << |
| NCT00226096 | CVA (Cerebrovascular Accident)... 展开 >> Cerebral Hemorrhage Intracranial Hemorrhages 收起 << | Not Applicable | Completed | - | Australia, New South Wales ... 展开 >> Concord Hospital Concord, New South Wales, Australia, 2138 Gosford Hospital Gosford, New South Wales, Australia, 2250 St George Hospital Kogarah, New South Wales, Australia, 2217 John Hunter Hospital Newcastle, New South Wales, Australia, 2310 St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Royal Prince Alfred Hospital Sydney, New South Wales, Australia, 2050 Westmead Hospital Westmead, New South Wales, Australia, 2145 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 Australia, Victoria Royal Melbourne Hospital Melbourne, Victoria, Australia, 3050 St Vincent's Hospital Melbourne, Victoria, Australia, 3065 Box Hill Hospital Melbourne, Victoria, Australia, 3128 Alfred Hospital Melbourne, Victoria, Australia, 3181 Austin Health Melbourne, Victoria, Australia Monash Medical Centre Melbourne, Victoria, Australia Australia, Western Australia Sir Charles Gairdner Hospital Perth, Western Australia, Australia, 6009 China Regional Coordinating Centre: Peking University First Hospital Beijing, China, 100034 Hospitals in China, c/o The George Institute China Beijing, China Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University Shanghai, China, 200025 New Zealand North Shore Hospital Auckland, New Zealand Christchurch Hospital Christchurch, New Zealand 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.65mL 0.53mL 0.26mL |
13.25mL 2.65mL 1.32mL |
26.49mL 5.30mL 2.65mL |
|
| CAS号 | 65-28-1 |
| 分子式 | C18H23N3O4S |
| 分子量 | 377.46 |
| SMILES Code | CS(O)(=O)=O.CC1=CC=C(N(C2=CC(O)=CC=C2)CC3=NCCN3)C=C1 |
| MDL No. | MFCD00134201 |
| 别名 | Phentolamine methanesulfonate; Phentolamine mesylate; Phentolamine (mesylate) |
| 运输 | 蓝冰 |
| InChI Key | OGIYDFVHFQEFKQ-UHFFFAOYSA-N |
| Pubchem ID | 91430 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Sealed in dry,2-8°C |
| 溶解方案 |
H2O: 50 mg/mL(132.47 mM) 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1